<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03536117</url>
  </required_header>
  <id_info>
    <org_study_id>MTBVAC-03</org_study_id>
    <nct_id>NCT03536117</nct_id>
  </id_info>
  <brief_title>Dose-Defining Safety and Immunogenicity Study of MTBVAC in South African Neonates</brief_title>
  <official_title>Phase 2a Dose-Defining Safety and Immunogenicity Study of MTBVAC in South African Neonates Living in a High-Burden Tuberculosis-Endemic Region</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biofabri, S.L</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>South African Tuberculosis Vaccine Initiative</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universidad de Zaragoza</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>TuBerculosis Vaccine Initiative</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Biofabri, S.L</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A new effective tuberculosis (TB) vaccine is essential to achieve World Health Organization
      (WHO) End TB goals and eliminate TB by 2050. The optimal long-term strategy would be a
      combination of serial mass campaigns in adults, coupled with universal newborn vaccination.
      Newborns are the only human population without prior mycobacterial exposure in TB endemic
      countries and as such, live attenuated mycobacterial vaccines may offer better protection to
      this naïve population compared to adults.

      MTBVAC is a novel TB vaccine candidate generated by genetically attenuating an M.
      tuberculosis clinical isolate of the EuroAmerican lineage. MTBVAC is based on two
      independent, stable genetic deletions of the genes coding for two major virulence factors,
      phoP coding for the transcription factor PhoP and fadD26 coding for the synthesis of PDIM.
      Since MTBVAC contains most of the genes deleted from BCG, it presents a wider collection of
      mycobacterial antigens to the host immune system. Safety and immunogenicity of MTBVAC has
      been demonstrated in BCG naïve adults; and MTBVAC appears safe in a small ongoing Phase 1b
      study in South African newborns. Definitive demonstration of safety and immunogenicity at the
      optimal MTBVAC dose is key to progression into multi-centre efficacy trials in newborns.

      A Phase 2a dose-defining study of MTBVAC to evaluate the safety, reactogenicity,
      immunogenicity, and potential for IGRA conversion and reversion, of MTBVAC in South African
      newborns. Ninety-nine HIV unexposed, BCG naïve newborns will be randomized to receive either
      BCG 2.5 x 105 CFU (n=24) or MTBVAC at one of three dose levels (n=75). Allocation will be
      double blind. Enrolment will be sequential into 3 cohorts of increasing MTBVAC dose (Cohort
      1: n=25 MTBVAC 2.5 x 10E+04 and n=8 BCG; Cohort 2: n=25 MTBVAC 2.5 x 10E+05 and n=8 BCG;
      Cohort 3: n=25 MTBVAC 2.5 x 10E+06 and n=8 BCG). Dose escalation will be staggered to allow
      gradual evaluation of safety; final selection of the dose for Cohort 3 will be based on all
      available safety and immunogenicity data.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2018</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events as defined in protocol.</measure>
    <time_frame>360 days post-vaccination</time_frame>
    <description>Solicited systemic adverse events: fever, irritability, vomiting, diarrhea, drowsiness, poor feeding, skin rash.
Solicited injection site reaction adverse events: pain, redness, swelling, ulceration, drainage, and regional lymphadenopathy
Unsolicited adverse events and serious adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity analysis in infants</measure>
    <time_frame>360 days post-vaccination</time_frame>
    <description>Measure of CD4 and CD8 T cells expressing specific cytokines in whole blood.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MTBVAC-induced QFT conversion and reversion kinetics</measure>
    <time_frame>360 days post-vaccination</time_frame>
    <description>Measure of ESAT-6 and CFP-10 reactivity in blood, as per the current QuantiFERON TB test</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">99</enrollment>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>MTBVAC Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MTBVAC intermediate dose 2.5 x 10E+04 CFU/0.05 mL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MTBVAC Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MTBVAC high dose 2.5 x 10E+05 CFU/0.05 mL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MTBVAC Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MTBVAC highest dose 2.5 x 10E+06 CFU/0.05 mL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BCG Group 4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>BCG control 2.5 x 10E+05 CFU/0.05 mL</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MTBVAC</intervention_name>
    <description>Live-attenuated Mycobacterium tuberculosis based on the deletion of phoP and fadD26 virulence genes</description>
    <arm_group_label>MTBVAC Group 1</arm_group_label>
    <arm_group_label>MTBVAC Group 2</arm_group_label>
    <arm_group_label>MTBVAC Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BCG</intervention_name>
    <description>Live-attenuated Mycobacterium bovis obtained by subculture passaging in ox-bile and glycerated potatoes between 1908-1921 by Albert Calmette and Camille Guerin. BCG is the only licensed vaccine today against tuberculosis (TB) mainly used in TB-endemic countries.</description>
    <arm_group_label>BCG Group 4</arm_group_label>
    <other_name>Licensed BCG</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria of Newborns:

          -  Newborns of mothers who provided informed consent will be enrolled within 96 hours of
             birth if they are in general good health during pregnancy and delivery

          -  Weight ≥2450 grams at birth

          -  Apgar score at 5 minutes ≥7

          -  Estimated gestational age ≥37 weeks.

        Exclusion Criteria of Newborns:

          -  If received routine BCG vaccination prior to enrolment

          -  Have any significant antenatal or intrapartum or postpartum complications

          -  Have unknown or positive maternal HIV test; or

          -  Have prior history of close contact with a TB patient, antenatal or postnatal, whether
             maternal, other family member or other household member.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>96 Hours</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michele Tameres, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Study Principal Investigator South African Tuberculosis Vaccine Initiative</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ingrid Murillo, BSc</last_name>
    <phone>976330400</phone>
    <phone_ext>361</phone_ext>
    <email>ingrid.murillo@biofabri.es</email>
  </overall_contact>
  <reference>
    <citation>Arbues A, Aguilo JI, Gonzalo-Asensio J, Marinova D, Uranga S, Puentes E, Fernandez C, Parra A, Cardona PJ, Vilaplana C, Ausina V, Williams A, Clark S, Malaga W, Guilhot C, Gicquel B, Martin C. Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trials. Vaccine. 2013 Oct 1;31(42):4867-73. doi: 10.1016/j.vaccine.2013.07.051. Epub 2013 Aug 17.</citation>
    <PMID>23965219</PMID>
  </reference>
  <reference>
    <citation>Spertini F, Audran R, Chakour R, Karoui O, Steiner-Monard V, Thierry AC, Mayor CE, Rettby N, Jaton K, Vallotton L, Lazor-Blanchet C, Doce J, Puentes E, Marinova D, Aguilo N, Martin C. Safety of human immunisation with a live-attenuated Mycobacterium tuberculosis vaccine: a randomised, double-blind, controlled phase I trial. Lancet Respir Med. 2015 Dec;3(12):953-62. doi: 10.1016/S2213-2600(15)00435-X. Epub 2015 Nov 17.</citation>
    <PMID>26598141</PMID>
  </reference>
  <reference>
    <citation>Aguilo N, Uranga S, Marinova D, Monzon M, Badiola J, Martin C. MTBVAC vaccine is safe, immunogenic and confers protective efficacy against Mycobacterium tuberculosis in newborn mice. Tuberculosis (Edinb). 2016 Jan;96:71-4. doi: 10.1016/j.tube.2015.10.010. Epub 2015 Nov 30.</citation>
    <PMID>26786657</PMID>
  </reference>
  <reference>
    <citation>Clark S, Lanni F, Marinova D, Rayner E, Martin C, Williams A. Revaccination of Guinea Pigs With the Live Attenuated Mycobacterium tuberculosis Vaccine MTBVAC Improves BCG's Protection Against Tuberculosis. J Infect Dis. 2017 Sep 1;216(5):525-533. doi: 10.1093/infdis/jix030.</citation>
    <PMID>28329234</PMID>
  </reference>
  <reference>
    <citation>Marinova D, Gonzalo-Asensio J, Aguilo N, Martin C. MTBVAC from discovery to clinical trials in tuberculosis-endemic countries. Expert Rev Vaccines. 2017 Jun;16(6):565-576. doi: 10.1080/14760584.2017.1324303. Epub 2017 May 12. Review.</citation>
    <PMID>28447476</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 16, 2018</study_first_submitted>
  <study_first_submitted_qc>May 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2018</study_first_posted>
  <last_update_submitted>May 14, 2018</last_update_submitted>
  <last_update_submitted_qc>May 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

